Innovation is in our DNA
Our strategy is innovation. QuantaMatrix has developed innovative platforms and solutions for Clinical Microbiology and Molecular/Immunoassay applications. Our ultimate goal is to become a global leader in sepsis diagnostics.
dRAST (direct & Rapid Antimicrobial Susceptibility Test) is generating awareness in the infectious diseases and clinical microbiology community due to the ever increasing need to tackle Antimicrobial Resistance, especially so-called Superbugs, and support Antibiotic Stewardship efforts. While conventional AST can take 3 days to generate results, dRAST results are available in as little as 4 hours saving days to get critical, therapy guiding information to clinicians. Our technology and products will dramatically improve patient care and save lives.
A Pioneer in IVD
Our pipeline encompasses rapid antimicrobial susceptibility test for sepsis and tuberculosis, Alzheimer’s disease, and Cardiovascular disease. QuantaMatrix aims to become pioneer in the In Vitro Diagnostic (IVD) industry and significant improve public health around the world.
Dr. SungHoon Kwon, President and CEO